Company profile
AUTOLUS THERAPEUTICS PLC
NASDAQ:AUTLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AUCATZYL | approved | $45.7MQ2 2026 | 5 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04404660 | phase1_2 | active_not_recruiting | 2020-06-03 | 2029-06-30 | Autolus Limited | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
| NCT06173518 | phase1 | recruiting | 2023-11-16 | 2027-11-01 | Autolus Limited | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) |
| NCT03287804 | phase1_2 | terminated | 2017-05-05 | 2019-09-05 | Autolus Limited | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma |
| NCT03289455 | phase1_2 | completed | 2017-06-26 | 2020-05-18 | Autolus Limited | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) |
| NCT03287817 | phase1_2 | terminated | 2017-09-05 | 2023-10-19 | Autolus Limited | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125813 | 2024-11-08 | BLA | AUTOLUS, INC. | |||||
Loading… | ||||||||